Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty).
Combination inhaled therapy probably leads to higher total adverse events compared with SABA alone (moderate certainty).
It is very uncertain whether inhaled corticosteroids plus standard care changes serious adverse events compared with standard care (with or without placebo) (very low certainty).
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
As‐required FABA/ICS inhalers showed no clear difference in adverse events compared with regular inhaled steroid (moderate certainty).
It is very uncertain whether increased changes serious adverse events 48 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
Hypertonic saline showed no clear difference in adverse events compared with isotonic saline; GRADE not reported.
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
Simplified showed no clear difference in all adverse events compared with usual regimens (low certainty).
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
The intervention showed no clear difference in serious adverse events (moderate certainty).
The intervention showed no clear difference in serious adverse events (moderate certainty).